Sleep Medicine and Psychophysiology (수면정신생리)

KOREAN ACADEMY OF SLEEP MEDICINE (대한수면의학회)
권호 표지
DOI QR코드

DOI QR Code

Updates on the Treatment of Restless Legs Syndrome

하지불안증후군 치료의 최신지견

  • Kang, Seung-Gul (Department of Psychiatry, Gil Medical Center, Gachon University, College of Medicine)
  • 강승걸 (가천대학교 의과대학 길병원 정신건강의학교실)
  • Received : 2018.03.05
  • Accepted : 2018.04.20
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Restless legs syndrome (RLS) is a sleep disorder characterized by an urge to move the legs or arms and uncomfortable paresthesia in the legs. Treatment of RLS can be various depending on the causes, severity, and frequency of the symptoms. In the case of secondary RLS, it is important to identify and manage the cause of RLS. Dopamine agonists have been used as firstline treatments for primary RLS treatment. However, due to augmentation, which is a common side effect of dopamine agonists, recent treatment guidelines are changing to prefer to anticonvulsants such as pregabalin and gabapentin. Iron, opioid, or benzodiazepine may be used when anticonvulsants or dopamine agonists are not adequately treated. Because RLS is a chronic disease, it is essential to establish a long-term treatment plan considering both efficacy and side effects.

Keywords

References

  1. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 1997;20:148-151. https://doi.org/10.1097/00002826-199704000-00006
  2. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011;12:906-913. https://doi.org/10.1016/j.sleep.2011.06.009
  3. Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014;370:621-631. https://doi.org/10.1056/NEJMoa1303646
  4. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213. https://doi.org/10.1093/sleep/19.3.205
  5. Allen RP, Montplaisir J, Walters AS, Ferini-Strambi L, Hogl B. Restless Legs Syndrome and Periodic Limb Movements During Sleep. In: Kryger M, Roth T. Principles and Practice of Sleep Medicine (Sixth Edition). Philadelpha: Elsevier;2017. p.923-934.
  6. Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 2011;12:431-439. https://doi.org/10.1016/j.sleep.2011.03.003
  7. Bogan RK, Bornemann MA, Kushida CA, Tran PV, Barrett RW. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010;85:512-521. https://doi.org/10.4065/mcp.2009.0700
  8. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-1579. https://doi.org/10.1212/WNL.59.10.1573
  9. Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 2016;21:1-11. https://doi.org/10.1016/j.sleep.2016.01.017
  10. Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim YK, et al. Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1078-1083. https://doi.org/10.1016/j.pnpbp.2007.03.011
  11. Koo YS, Kim SM, Lee C, Lee BU, Moon YJ, Cho YW, et al. Transcranial direct current stimulation on primary sensorimotor area has no effect in patients with drug-naive restless legs syndrome: a proof-of-concept clinical trial. Sleep Med 2015;16:280-7. https://doi.org/10.1016/j.sleep.2014.07.032
  12. Kurlan R, Rabin M. Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy. J Parkinsonism Restless Legs Syndr 2013;3:49-52.
  13. Lettieri CJ, Eliasson AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial. Chest 2009;135:74-80. https://doi.org/10.1378/chest.08-1665
  14. Manconi M, Ferri R, Zucconi M, Bassetti CL, Fulda S, Arico D, et al. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol 2012;71:834-844. https://doi.org/10.1002/ana.23565
  15. Mellick GA, Mellick LB. Management of restless legs syndrome with gabapentin (Neurontin). Sleep 1996;19:224-226. https://doi.org/10.1093/sleep/19.3.224
  16. Mitchell UH, Myrer JW, Johnson AW, Hilton SC. Restless legs syndrome and near-infrared light: An alternative treatment option. Physiother Theory Pract 2011;27:345-351. https://doi.org/10.3109/09593985.2010.511440
  17. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-1635. https://doi.org/10.1002/mds.21050
  18. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-943. https://doi.org/10.1212/WNL.52.5.938
  19. Phillips B, Hening W, Britz P, Mannino D. Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll. Chest 2006;129:76-80. https://doi.org/10.1378/chest.129.1.76
  20. Rios Romenets S, Dauvilliers Y, Cochen De Cock V, Carlander B, Bayard S, Galatas C, et al. Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease. Parkinsonism Relat Disord 2013;19:92-94. https://doi.org/10.1016/j.parkreldis.2012.07.019
  21. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16:1159-1163. https://doi.org/10.1002/mds.1209
  22. Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2016;87:2585-2593. https://doi.org/10.1212/WNL.0000000000003388
  23. Winkelman JW, Johnston L. Augmentation and tolerance with longterm pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14. https://doi.org/10.1016/j.sleep.2003.07.005
  24. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008;70:35-42. https://doi.org/10.1212/01.wnl.0000287072.93277.c9